{"id":"gliclazide","rwe":[],"tags":[{"label":"gliclazide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"ABCC9","category":"gene"},{"label":"A10BB09","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1291.361,"date":"","count":886,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 886 times (LLR=1291)"},{"llr":976.258,"date":"","count":633,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 633 times (LLR=976)"},{"llr":876.694,"date":"","count":1543,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 1,543 times (LLR=877)"},{"llr":705.823,"date":"","count":368,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 368 times (LLR=706)"},{"llr":608.842,"date":"","count":368,"signal":"Diabetic ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 368 times (LLR=609)"},{"llr":460.435,"date":"","count":509,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 509 times (LLR=460)"},{"llr":332.379,"date":"","count":355,"signal":"Hyperglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 355 times (LLR=332)"},{"llr":268.013,"date":"","count":101,"signal":"Diabetic metabolic decompensation","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=268)"},{"llr":258.995,"date":"","count":322,"signal":"Metabolic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 322 times (LLR=259)"},{"llr":229.324,"date":"","count":108,"signal":"Euglycaemic diabetic ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 108 times (LLR=229)"},{"llr":194.805,"date":"","count":152,"signal":"Glycosylated haemoglobin increased","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=195)"},{"llr":190.362,"date":"","count":92,"signal":"Hyperlactacidaemia","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=190)"},{"llr":182.324,"date":"","count":85,"signal":"Hypoglycaemic coma","source":"DrugCentral FAERS","actionTaken":"Reported 85 times (LLR=182)"},{"llr":152.554,"date":"","count":113,"signal":"Pemphigoid","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=153)"},{"llr":150.726,"date":"","count":334,"signal":"Blood glucose increased","source":"DrugCentral FAERS","actionTaken":"Reported 334 times (LLR=151)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GLICLAZIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:25:49.625326+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:25:57.639346+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLICLAZIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:25:57.943724+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:25:59.001105+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL427216/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:25:58.654615+00:00"}},"allNames":"diabyl","offLabel":[],"synonyms":["gliclazide","diabezidum","diabrezide","diabyl","diaprel","glimicron","glinormax","glyzide","gliclazid","dizalid","S 1702"],"timeline":[{"date":"1972-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1972-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Diabyl","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"},{"gene":"ABCC9","source":"DrugCentral","target":"Sulfonylurea receptor 2, Kir6.2","protein":"ATP-binding cassette sub-family C member 9"},{"gene":"AKR1C3","source":"DrugCentral","target":"Aldo-keto reductase family 1 member C3","protein":"Aldo-keto reductase family 1 member C3"}],"modality":"Small Molecule","drugClass":"gliclazide","explanation":"","oneSentence":"","technicalDetail":"Gliclazide binds to the Sulfonylurea receptor 1 (SUR1), a regulatory subunit of the ATP-sensitive potassium channel (K_ATP), composed of Kir6.2 subunits. This binding causes a conformational change that leads to the closure of the potassium channel, depolarization of the beta cell membrane, and an increase in insulin secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1299","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GLICLAZIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLICLAZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:45:27.316343","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:26:00.353347+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"gliclazide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03499808","phase":"PHASE2","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2018-06-06","conditions":["Amorphous, Eosinophilic, and Acellular Deposit","Constipation","Diarrhea","Early Satiety","Gastrointestinal Hemorrhage","Hepatomegaly","Lymphadenopathy","Macroglossia","Nausea","Primary Systemic Amyloidosis","Purpura","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":43,"completionDate":"2023-09-19"},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":["Renal Insufficiency, Chronic"],"enrollment":70,"completionDate":"2027-12-31"},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":["Diabetes Mellitus Type 2"],"enrollment":150,"completionDate":"2026-10-01"},{"nctId":"NCT06085703","phase":"NA","title":"Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-01","conditions":["Type 2 Diabetes Mellitus","Mild Cognitive Impairment"],"enrollment":24,"completionDate":"2025-06-30"},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":["Type 2 Diabetes Mellitus"],"enrollment":243,"completionDate":"2012-04-25"},{"nctId":"NCT00145925","phase":"PHASE3","title":"Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"The George Institute","startDate":"2001-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":11140,"completionDate":"2008-03"},{"nctId":"NCT06708091","phase":"","title":"Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2022-02-15","conditions":["Type 2 Diabetes"],"enrollment":537,"completionDate":"2024-05-31"},{"nctId":"NCT06704802","phase":"","title":"Observational Cohort Study Evaluating the Effectiveness of an Education Program (NGAYDAUTIEN) in Combination With Gliclazide MR in the Management of Uncontrolled Type 2 Diabetic Patients.","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2022-11-04","conditions":["Type 2 Diabetes"],"enrollment":678,"completionDate":"2024-06-28"},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":90,"completionDate":"2027-12"},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":["Type 2 Diabetes Mellitus","Glucotoxicity"],"enrollment":129,"completionDate":"2024-07-01"},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":["Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin"],"enrollment":200,"completionDate":"2024-08-30"},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":["Type2diabetes"],"enrollment":938,"completionDate":"2025-06"},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":["Type 2 Diabetes"],"enrollment":78,"completionDate":"2023-12-31"},{"nctId":"NCT06222476","phase":"NA","title":"Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.","status":"NOT_YET_RECRUITING","sponsor":"Yan Bi","startDate":"2024-02-20","conditions":["Diabetic Nephropathy Type 2"],"enrollment":106,"completionDate":"2026-06-30"},{"nctId":"NCT06217887","phase":"NA","title":"Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-05-10","conditions":["Type 2 Diabetes Mellitus","Cognitive Function Abnormal"],"enrollment":58,"completionDate":"2024-06"},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":170,"completionDate":"2022-08-31"},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":1147,"completionDate":"2010-11-04"},{"nctId":"NCT03246828","phase":"NA","title":"Glucagon in MODY (Maturity Onset Diabetes of the Young)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-07-03","conditions":["MODY1","MODY3"],"enrollment":10,"completionDate":"2022-08-01"},{"nctId":"NCT03433248","phase":"PHASE4","title":"Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES","status":"UNKNOWN","sponsor":"M.H.H. Kramer","startDate":"2017-11-09","conditions":["Type2 Diabetes"],"enrollment":66,"completionDate":"2022-09-01"},{"nctId":"NCT04198948","phase":"PHASE1","title":"Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers","status":"COMPLETED","sponsor":"University of Sarajevo","startDate":"2019-03-04","conditions":["Diabetes Mellitus, Type 2"],"enrollment":15,"completionDate":"2019-08-05"},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":["Type 2 Diabetes"],"enrollment":30,"completionDate":"2020-12-02"},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":119,"completionDate":"2019-11-19"},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1007,"completionDate":"2009-01"},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":["Diabetes Mellitus, Type 2","Diabetic Nephropathies"],"enrollment":44,"completionDate":"2018-09"},{"nctId":"NCT04443777","phase":"PHASE4","title":"Analysis of Ergogenic Potential and Risks Associated With Acute and Chronic Use of Sulphonylureas on Physical Exercise","status":"UNKNOWN","sponsor":"Instituto de Cardiologia do Rio Grande do Sul","startDate":"2020-06-01","conditions":["Resistance Training","Sport Performance","Muscle Recovery","Hypoglycemic Agents","Randomized Controlled Trial"],"enrollment":44,"completionDate":"2020-09-01"},{"nctId":"NCT04132934","phase":"","title":"Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2019-03-11","conditions":["Type 2 Diabetes"],"enrollment":1200,"completionDate":"2019-10-04"},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":["Psoriasis","Type 2 Diabetes Mellitus"],"enrollment":20,"completionDate":"2016-01"},{"nctId":"NCT00736515","phase":"PHASE4","title":"Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes","status":"COMPLETED","sponsor":"Servier (Tianjin) Pharmaceutical Co. LTD.","startDate":"2008-10","conditions":["Type 2 Diabetes"],"enrollment":160,"completionDate":"2011-08"},{"nctId":"NCT02925559","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2016-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":135,"completionDate":"2019-01"},{"nctId":"NCT03705195","phase":"NA","title":"Study of Sulphonylurea Synergy With Incretins","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-08-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":20,"completionDate":"2019-06-26"},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":800,"completionDate":"2020-05"},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":25,"completionDate":"2018-09-13"},{"nctId":"NCT03467945","phase":"PHASE1","title":"Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-02-16","conditions":["Healthy"],"enrollment":40,"completionDate":"2018-04-29"},{"nctId":"NCT03467971","phase":"PHASE1","title":"A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-06","conditions":["Healthy"],"enrollment":21,"completionDate":"2018-04-22"},{"nctId":"NCT02610088","phase":"PHASE4","title":"Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11","conditions":["Diabetes"],"enrollment":32,"completionDate":"2018-09"},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":585,"completionDate":"2014-05-08"},{"nctId":"NCT03313661","phase":"PHASE3","title":"Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-14","conditions":["Diabetes"],"enrollment":60,"completionDate":"2020-12"},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":5570,"completionDate":"2015-04-17"},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":498,"completionDate":"2014-06-24"},{"nctId":"NCT03196154","phase":"","title":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2017-08-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":255,"completionDate":"2018-03-30"},{"nctId":"NCT01847144","phase":"PHASE4","title":"MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2013-04","conditions":["Type 2 Diabetes"],"enrollment":143,"completionDate":"2015-02"},{"nctId":"NCT00738088","phase":"PHASE4","title":"Variation in Sulphonylurea Response in Type 2 Diabetes","status":"TERMINATED","sponsor":"NHS Tayside","startDate":"2007-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":14,"completionDate":"2011-03-03"},{"nctId":"NCT02092597","phase":"PHASE4","title":"Safety Evaluation of Adverse Reactions in Diabetes","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2013-10","conditions":["Type 2 Diabetes Mellitus"],"enrollment":42,"completionDate":"2016-09"},{"nctId":"NCT00780715","phase":"PHASE4","title":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2008-12","conditions":["Diabetes Mellitus, Type 2"],"enrollment":29,"completionDate":"2009-10"},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":["Type 2 Diabetes Mellitus"],"enrollment":870,"completionDate":"2011-09-21"},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":427,"completionDate":"2012-01-19"},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":3453,"completionDate":"2013-08-31"},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":["Uncontrolled Type 2 Diabetes Mellitus"],"enrollment":250,"completionDate":"2017-04-01"},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":["Type 2 Diabetes"],"enrollment":350,"completionDate":"2015-02"},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":["Diabetes Mellitus, Type 2"],"enrollment":4447,"completionDate":"2008-12"},{"nctId":"NCT03068065","phase":"PHASE4","title":"Antidiabetic Effects on Intrahepatic Fat","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2014-05","conditions":["Non-Alcoholic Fatty Liver Disease","Type2 Diabetes"],"enrollment":87,"completionDate":"2015-10"},{"nctId":"NCT02980757","phase":"PHASE1","title":"Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets","status":"WITHDRAWN","sponsor":"Disphar International B.V.","startDate":"2014-06","conditions":["Comparative Bioavailability"],"enrollment":0,"completionDate":""},{"nctId":"NCT00102388","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1092,"completionDate":""},{"nctId":"NCT01679899","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2012-12","conditions":["Type 2 Diabetes Mellitus","Menopause","Osteoporosis","Osteopenia"],"enrollment":56,"completionDate":"2015-10"},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":["Type 2 Diabetes"],"enrollment":5000,"completionDate":"2015-10"},{"nctId":"NCT02201602","phase":"PHASE4","title":"Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-08","conditions":["Diabetes"],"enrollment":8,"completionDate":"2016-07"},{"nctId":"NCT02643329","phase":"PHASE1","title":"Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations","status":"COMPLETED","sponsor":"Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited","startDate":"2016-01","conditions":["Healthy"],"enrollment":17,"completionDate":"2016-04"},{"nctId":"NCT02777671","phase":"PHASE1","title":"Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-10","conditions":["Epilepsy"],"enrollment":20,"completionDate":"2007-12"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"},{"nctId":"NCT02587741","phase":"EARLY_PHASE1","title":"Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":["Diabetic Retinopathy"],"enrollment":600,"completionDate":"2025-07"},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease"],"enrollment":3371,"completionDate":"2018-12"},{"nctId":"NCT01269996","phase":"PHASE4","title":"JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":71,"completionDate":"2015-02"},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":70,"completionDate":"2016-09"},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":361,"completionDate":"2013-07"},{"nctId":"NCT01022762","phase":"PHASE4","title":"Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":440,"completionDate":"2010-11"},{"nctId":"NCT00949286","phase":"","title":"Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study","status":"COMPLETED","sponsor":"The George Institute","startDate":"2010-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":8494,"completionDate":"2014-02"},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1,"completionDate":"2010-01"},{"nctId":"NCT01758380","phase":"PHASE4","title":"Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":557,"completionDate":"2013-09"},{"nctId":"NCT01963130","phase":"","title":"Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2012-07","conditions":["Drug Mechanism","Drug Usage"],"enrollment":97,"completionDate":"2013-07"},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":["Type 2 Diabetes"],"enrollment":60,"completionDate":"2011-12"},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":["Diabetes"],"enrollment":47,"completionDate":"2012-06"},{"nctId":"NCT01771185","phase":"NA","title":"Metabolic Effects of Gastrointestinal Surgery in T2DM","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-10","conditions":["Type 2 Diabetes"],"enrollment":24,"completionDate":"2013-12"},{"nctId":"NCT00830297","phase":"PHASE2","title":"Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia","status":"COMPLETED","sponsor":"Marcus Saemann","startDate":"2009-01","conditions":["Hyperglycemia"],"enrollment":50,"completionDate":"2011-05"},{"nctId":"NCT01420692","phase":"NA","title":"The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ankara University","startDate":"2010-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":64,"completionDate":"2012-06"},{"nctId":"NCT01426737","phase":"PHASE4","title":"The Swiss Glucose Variability Study","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2011-04","conditions":["Type 2 Diabetes"],"enrollment":50,"completionDate":"2013-01"},{"nctId":"NCT00808860","phase":"PHASE1,PHASE2","title":"Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Hanoi Medical University","startDate":"2008-02","conditions":["Type 2 Diabetes"],"enrollment":25,"completionDate":"2008-12"},{"nctId":"NCT01195532","phase":"","title":"An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2010-01","conditions":["Hyperglycemia","Diabetes"],"enrollment":40,"completionDate":"2011-01"},{"nctId":"NCT00367055","phase":"PHASE4","title":"Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":["Type 2 Diabetes Mellitus"],"enrollment":84,"completionDate":"2008-10"},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":387,"completionDate":""},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":436,"completionDate":"2007-10"},{"nctId":"NCT00169624","phase":"PHASE3","title":"Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2005-10","conditions":["Coronary and Peripheral Endothelial Dysfunction"],"enrollment":30,"completionDate":""},{"nctId":"NCT00464594","phase":"NA","title":"Japan Early Diabetes Intervention Study","status":"UNKNOWN","sponsor":"Japan Early Diabetes Intervention Study Group","startDate":"2007-04","conditions":["Diabetes Mellitus"],"enrollment":2560,"completionDate":""},{"nctId":"NCT00225342","phase":"PHASE4","title":"Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina","status":"WITHDRAWN","sponsor":"University of Glasgow","startDate":"","conditions":["Angina Pectoris","Diabetes Mellitus, Type 2"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166470","NDDF":"003858","UNII":"G4PX8C4HKV","CHEBI":"CHEBI:31654","INN_ID":"3056","RXNORM":"4816","UMLSCUI":"C0017631","chemblId":"CHEMBL427216","ChEMBL_ID":"CHEMBL427216","KEGG_DRUG":"D01599","DRUGBANK_ID":"DB01120","PDB_CHEM_ID":" GCZ","PUBCHEM_CID":"3475","SNOMEDCT_US":"325238000","MESH_DESCRIPTOR_UI":"D005907"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"16.4 hours","clearance":"0.41 mL/min/kg","bioavailability":"97%","fractionUnbound":"0.03%","volumeOfDistribution":"0.43 L/kg"},"publicationCount":1501,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB09","allCodes":["A10BB09"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1972-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:26:00.353347+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}